Keystone Nano said today that its ceramide nanoliposome won orphan drug status for the treatment of liver cancer. The designation provides the company with a window of market exclusivity upon product approval.
The State College, Penn.-based company touted its nanoliposome delivery system as being able to load both water-loving and water-hating compounds and delivery them intracellularly. The carriers range from 60-80 nanometers and are stable in circulating blood.
Get the full story at our sister site, Drug Delivery Business News.